A Phase I, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS5001, an Anti-ROR1 Antibody Drug Conjugate, in Patients With Advanced Solid Tumors and Lymphomas
NCT #
NCT05279300
Condition(s)
Breast Cancer, Lymphoma, Lymphoma (Diffuse Large B-cell), Solid Tumor
Molecular Target(s)
ROR1
Drug Classification(s)
Antibody Drug Conjugate, Targeted Therapy
Agents(s)
CS5001
Phase(s)
I
Mechanism of Action
CS5001 is a highly differentiated Antibody Drug Conjugate targeting ROR1. ROR1 is expressed across a variety of cancers, and may play an important role in oncogenesis by activating cell survival signaling events.
Purpose
- How much of the study agent can be given with an acceptable level of side effects
- The effects of the study agent (good and bad)
- How much of the study agent is absorbed into the blood and how fast it is removed
Location
MCD
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.